| Revenue Growth | Q3 revenue $253.7M, up 177% YoY; Florida retail grew 34% QoQ. |
|---|---|
| Mgmt Confidence | High confidence in turnaround strategy; providing first-ever formal sequential quarterly guidance. |
| Demand Visibility | Visibility limited to immediate operational horizons; sequential guidance adopted for agility. |
| Margin Trends | Adjusted EBITDA $42.7M; Q4 guidance 18% margin; Q1 2027 margin 18.8%. |
| Op. Leverage | Leveraging scale to drive performance; shared services across THC and non-THC. |
| Pricing Power | Facing mid-single digit cannabis price deflation; retail same-store growth at 4%. |
| Vol vs Price | Growth driven by M&A volume; retail organic growth 4% despite deflation. |
| Segment Growth | Florida up 34%; Minnesota down 10%; Colorado now 25% of retail. |
| New Clients | Acquired Pharmacan Colorado, C-21, M-3 Wellness, and Fluent Florida operations. |
| Capex & Debt | Net debt $166.2M; $60M real estate loan at 8.5% fixed rate. |
| Regulatory | Monitoring DEA registrations in Florida and pending approvals in Ohio. |
| Commentary | Focus on 'boiling a million eggs'—executing simple retail excellence at scale. |
| New Launches | Expanding into Ohio; opening second cultivation facility in Minnesota. |
Growth
Q3 revenue rose 177% year-over-year to $253.7 million; pro-forma revenue reached $277 million.
Outlook
Q4 2026 revenue guided to $250M-$265M; Q1 2027 revenue guided to $280M-$300M.
Risks
Management pivoted on Minnesota's 10% retail decline, blaming supply issues and lack of flower.
The company's earnings call, OTC: VREOF, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Vireo Growth Inc.: key numbers
- Share price
- $6.29Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Vireo Growth Inc.
All →Vireo Growth Q3 2026 Results: Net Loss of $24M, Loss Narrows
Vireo Growth Inc. reported a significant revenue increase to $253.7 million for the quarter ended September 30, 2026, compared to $91.7 million in the prior year, driven by multiple acquisitions including Eaze, Hawthorne, and C21. Despite higher gross profits, the company recorded a net loss of $24.0 million for the quarter, impacted by substantial current income tax expenses and transaction-related costs.
- Key figure
- Net loss $24M
Vireo Growth Financial Results
Vireo Growth reported Q3 2026 GAAP revenue of $253.7 million, a 177% increase year-over-year driven by recent M&A activity. The company achieved an annualized revenue run rate exceeding $1 billion and ended the quarter with $106.8 million in cash. Management highlighted the continued execution of its consolidation strategy and the pending merger with Planet 13.
- Term
- Q3 2026
Vireo Growth $60M Debt Financing with Needham Bank
Vireo Growth Inc. entered into a $60 million term loan agreement with Needham Bank at a fixed interest rate of 8.50% per annum. The proceeds were used to refinance $49 million of existing senior debt related to its New York cultivation facility and to finance the $11 million acquisition of its Palatka, Florida cultivation facility. The loan is secured by first-priority mortgages on these properties and matures in April 2034.
- Value
- $60M
- Counterparty
- Needham Bank
- Term
- through April 2, 2034